Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02026960 · ClinicalTrials.gov registry record · NA
RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)
A NA study, sponsored by Duke University.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT02026960 is a NA study that was terminated before completion, run by Duke University. The registered enrollment target is 14 participants.
The verdict
NCT02026960, a NA study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
The primary objective is to evaluate methods for AGS-003 production from surgical (stage I) and metastatic biopsy (stage II) Renal Cell Carcinoma (RCC) and a small subset of other GU cancers (expansion cohort) specimens using core needle biopsy in subjects with RCC or other GU cancers. Specifically, this study will evaluate the feasibility of RNA amplification from total tumor RNA isolated from tissues obtained by core needle tumor biopsy.
Interventions
- DEVICE RNA extraction and amplification from biopsy specimens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2014-03 |
| Est. Completion | 2017-09-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02026960
The ClinicalTrials.gov registry entry for NCT02026960 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RNA extraction and amplification from biopsy specimens is the first listed.
NCT02026960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02026960 about?
NCT02026960 is a clinical study titled "RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)". The primary objective is to evaluate methods for AGS-003 production from surgical (stage I) and metastatic biopsy (stage II) Renal Cell Carcinoma (RCC) and a small subset of other GU cancers (expansion cohort) specimens using core needle biopsy in subjects with RCC or other GU cancers. Specifically,...
What is the current status of trial NCT02026960?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2014-03. Estimated completion is 2017-09-07.
What interventions are being tested in trial NCT02026960?
The interventions under investigation include: RNA extraction and amplification from biopsy specimens (DEVICE).
Who is sponsoring clinical trial NCT02026960?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.